Initial Therapy with FOLFOXIRI and Bevacizumab for Metastatic Colorectal Cancer
作者： Fotios Loupakis , Chiara Cremolini , Gianluca Masi , Sara Lonardi , Vittorina Zagonel
关键词:
摘要: BackgroundA fluoropyrimidine plus irinotecan or oxaliplatin, combined with bevacizumab (a monoclonal antibody against vascular endothelial growth factor), is standard first-line treatment for metastatic colorectal cancer. Before the introduction of bevacizumab, chemotherapy fluorouracil, leucovorin, and (FOLFOXIRI) showed superior efficacy as compared (FOLFIRI). In a phase 2 study, FOLFOXIRI promising activity an acceptable rate adverse effects. MethodsWe randomly assigned 508 patients untreated cancer to receive either FOLFIRI (control group) (experimental group). Up 12 cycles were administered, followed by fluorouracil until disease progression. The primary end point was progression-free survival. ResultsThe median survival 12.1 months in experimental group, compared...
elsevier.com
springer.com
poliambulanza.it 参考文章(15)
C.H. Köhne, R. Labianca, T. Price, W. Scheithauer, A. Sobrero, J. Tabernero, D. Aderka, S. Barroso, G. Bodoky, J.Y. Douillard, H. El Ghazaly, J. Gallardo, A. Garin, R. Glynne-Jones, K. Jordan, A. Meshcheryakov, D. Papamichail, P. Pfeiffer, I. Souglakos, S. Turhal, A. Cervantes, H.J. Schmoll, E. Van Cutsem, A. Stein, V. Valentini, B. Glimelius, K. Haustermans, B. Nordlinger, C.J. van de Velde, J. Balmana, J. Regula, I.D. Nagtegaal, R.G. Beets-Tan, D. Arnold, F. Ciardiello, P. Hoff, D. Kerr, ESMO Consensus Guidelines for management of patients with colon and rectal cancer. A personalized approach to clinical decision making Annals of Oncology. ,vol. 23, pp. 2479- 2516 ,(2012) , 10.1093/ANNONC/MDS236
Volker Heinemann, Ludwig Fischer von Weikersthal, Thomas Decker, Alexander Kiani, Ursula Vehling-Kaiser, Salah-Eddin Al-Batran, Tobias Heintges, Christian Lerchenmüller, Christoph Kahl, Gernot Seipelt, Frank Kullmann, Martina Stauch, Werner Scheithauer, Jörg Hielscher, Michael Scholz, Sebastian Müller, Hartmut Link, Norbert Niederle, Andreas Rost, Heinz-Gert Höffkes, Markus Moehler, Reinhard U Lindig, Dominik P Modest, Lisa Rossius, Thomas Kirchner, Andreas Jung, Sebastian Stintzing, FOLFIRI plus cetuximab versus FOLFIRI plus bevacizumab as first-line treatment for patients with metastatic colorectal cancer (FIRE-3): a randomised, open-label, phase 3 trial Lancet Oncology. ,vol. 15, pp. 1065- 1075 ,(2014) , 10.1016/S1470-2045(14)70330-4
Alfredo Falcone, Sergio Ricci, Isa Brunetti, Elisabetta Pfanner, Giacomo Allegrini, Cecilia Barbara, Lucio Crinò, Giovanni Benedetti, Walter Evangelista, Laura Fanchini, Enrico Cortesi, Vincenzo Picone, Stefano Vitello, Silvana Chiara, Cristina Granetto, Gianfranco Porcile, Luisa Fioretto, Cinzia Orlandini, Michele Andreuccetti, Gianluca Masi, Phase III Trial of Infusional Fluorouracil, Leucovorin, Oxaliplatin, and Irinotecan (FOLFOXIRI) Compared With Infusional Fluorouracil, Leucovorin, and Irinotecan (FOLFIRI) As First-Line Treatment for Metastatic Colorectal Cancer: The Gruppo Oncologico Nord Ovest Journal of Clinical Oncology. ,vol. 25, pp. 1670- 1676 ,(2007) , 10.1200/JCO.2006.09.0928
G. Masi, G. Allegrini, S. Cupini, L. Marcucci, E. Cerri, I. Brunetti, E. Fontana, S. Ricci, M. Andreuccetti, A. Falcone, First-line treatment of metastatic colorectal cancer with irinotecan, oxaliplatin and 5-fluorouracil/leucovorin (FOLFOXIRI): results of a phase II study with a simplified biweekly schedule Annals of Oncology. ,vol. 15, pp. 1766- 1772 ,(2004) , 10.1093/ANNONC/MDH470
Richard M. Goldberg, Mace L. Rothenberg, Eric Van Cutsem, Al B. Benson, Charles D. Blanke, Robert B. Diasio, Axel Grothey, Heinz‐Josef Lenz, Neal J. Meropol, Ramesh K. Ramanathan, Carlos H. Roberto Becerra, Rita Wickham, Delma Armstrong, Carol Viele, The Continuum of Care: A Paradigm for the Management of Metastatic Colorectal Cancer Oncologist. ,vol. 12, pp. 38- 50 ,(2007) , 10.1634/THEONCOLOGIST.12-1-38
C.-H. Köhne, D. Cunningham, F. Di Costanzo, B. Glimelius, G. Blijham, E. Aranda, W. Scheithauer, P. Rougier, M. Palmer, J. Wils, B. Baron, F. Pignatti, P. Schöffski, S. Micheel, H. Hecker, Clinical determinants of survival in patients with 5-fluorouracil- based treatment for metastatic colorectal cancer: results of a multivariate analysis of 3825 patients Annals of Oncology. ,vol. 13, pp. 308- 317 ,(2002) , 10.1093/ANNONC/MDF034
Christophe Tournigand, Thierry André, Emmanuel Achille, Gérard Lledo, Michel Flesh, Dominique Mery-Mignard, Emmanuel Quinaux, Corinne Couteau, Marc Buyse, Gérard Ganem, Bruno Landi, Philippe Colin, Christophe Louvet, Aimery de Gramont, FOLFIRI Followed by FOLFOX6 or the Reverse Sequence in Advanced Colorectal Cancer: A Randomized GERCOR Study Journal of Clinical Oncology. ,vol. 22, pp. 229- 237 ,(2004) , 10.1200/JCO.2004.05.113
Patrick Therasse, Susan G. Arbuck, Elizabeth A. Eisenhauer, Jantien Wanders, Richard S. Kaplan, Larry Rubinstein, Jaap Verweij, Martine Van Glabbeke, Allan T. van Oosterom, Michaele C. Christian, Steve G. Gwyther, New Guidelines to Evaluate the Response to Treatment in Solid Tumors JNCI: Journal of the National Cancer Institute. ,vol. 92, pp. 205- 216 ,(2000) , 10.1093/JNCI/92.3.205
Leonard B. Saltz, Stephen Clarke, Eduardo Díaz-Rubio, Werner Scheithauer, Arie Figer, Ralph Wong, Sheryl Koski, Mikhail Lichinitser, Tsai-Shen Yang, Fernando Rivera, Felix Couture, Florin Sirzén, Jim Cassidy, Bevacizumab in Combination With Oxaliplatin-Based Chemotherapy As First-Line Therapy in Metastatic Colorectal Cancer: A Randomized Phase III Study Journal of Clinical Oncology. ,vol. 26, pp. 2013- 2019 ,(2008) , 10.1200/JCO.2007.14.9930
Alfredo Falcone, Gianluca Masi, Giacomo Allegrini, Romano Danesi, Elisabetta Pfanner, Isa Maura Brunetti, Antonello Di Paolo, Samanta Cupini, Mario Del Tacca, Pierfranco Conte, Biweekly Chemotherapy With Oxaliplatin, Irinotecan, Infusional Fluorouracil, and Leucovorin: A Pilot Study in Patients With Metastatic Colorectal Cancer Journal of Clinical Oncology. ,vol. 20, pp. 4006- 4014 ,(2002) , 10.1200/JCO.2002.12.075